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REVIEW
  Abstract: Patients with COPD most frequently complain of breathlessness and cough and these 
are both increased during exacerbations. Studies have generally focused on quality of life during 
end-stage disease, where breathlessness becomes dominant and cough less important. There are 
very little data on the frequency and severity of cough in COPD or its impact on quality of life 
at different stages of disease. Little is known about the factors that inﬂ  uence objective cough 
counts in COPD. Cough may be a marker for progressive disease in milder COPD patients who 
continue to smoke, and it may be useful in case-ﬁ  nding for milder disease in the community.
The cough reﬂ  ex sensitivity is heightened in COPD compared with healthy volunteers and 
similar to that in subjects with asthma. The degree of airﬂ  ow obstruction does not predict 
cough reﬂ  ex sensitivity or objective cough counts, implying an independent process. Effective 
treatments for cough in COPD have not yet been identiﬁ  ed. Improved outcome measures of 
cough, a better understanding of cough in the natural history of COPD, and its importance to 
patients are needed.
Keywords: cough, COPD, cough challenge
Introduction
Cough is an unfashionable topic, except for a few groups who are focused mainly on 
patients with chronic idiopathic cough. It is hard to understand why other causes of 
cough have not been studied in any detail. From the patients’ viewpoint, cough is the 
commonest reason for presentation to a primary care physician (Burt and Schappert 
2004), and can be associated with signiﬁ  cant morbidity, including rib fractures and 
stress incontinence. The relationship in many diseases, between cough frequency and 
severity, and quality of life is unexplored.
Cough has been largely ignored by the pharmaceutical industry, with no new 
effective anti-tussive in 100 years. This may be because symptom control does not ﬁ  t 
into a disease-orientated model, but also because the biological mechanisms underlying 
cough are not well understood and may involve complex lung–brain interactions. Much 
basic work has involved the guinea pig (Canning et al 2004), but to what extent this 
reﬂ  ects human cough is unclear. Many potential anti-tussives have been screened using 
cough reﬂ  ex sensitivity in humans (Morice 1996; Morice et al 2001). However, the 
relationship between cough reﬂ  ex sensitivity and objective cough counts is uncertain 
and it is possible that effective anti-tussives have been discarded for lack of appropriate 
clinical outcome measures in randomized studies.
COPD is characterized by airway inflammation and progressive airflow 
obstruction, most commonly caused by cigarette smoking. Cough, breathlessness, 
and sputum production are the major symptoms of which patients complain (Rennard 
et al 2002), although the relative importance depends on the stage of disease. The 
diagnostic criteria in the ﬁ  rst classiﬁ  cations of smoking-related lung disease (MRC 
1965) were based on the clinical patterns of symptoms and cough featured strongly. 
The deﬁ  nition of chronic bronchitis as “cough and sputum production for at least 3 
months of the year on two consecutive years”, was probably describing early or mild 
disease. A cross-sectional study has shown that patients with mild to moderate airﬂ  ow 
obstruction report cough and sputum production more frequently than those with 
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severe disease (von Hertzen et al 2000). However, as 
evidence accumulated that the degree of airﬂ  ow obstruction 
was a predictor of mortality (Fletcher and Peto 1977), 
the emphasis in patients with later stage disease then 
switched to breathlessness, and cough diminished in 
importance.
The recent Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) (Pauwels et al 2001) classifies 
patients with symptoms such as cough, but without airﬂ  ow 
obstruction as Stage 0 disease, suggesting that these patients 
are at risk of developing COPD. Evidence that cough is an 
important predictor of future progression in Stage 0 patients 
is lacking (Vestbo and Lange 2002), but a productive cough 
in the presence of already established airﬂ  ow obstruction, 
does predict FEV1 decline (Vestbo et al 1996) (Table 1). 
Consequently, cough may be a useful factor in case ﬁ  nding 
of patients at risk of progressive airﬂ  ow obstruction in the 
community. In a primary care study, age and cough were the 
best predictors of airﬂ  ow obstruction on spirometry (Van 
Schayck et al 2002) (Figure 1).
Why do patients with COPD cough?
There are a number of reasons why patients with COPD 
cough. First there is substantial airway inﬂ  ammation. Using 
techniques including bronchoalveolar lavage (Rutgers 
et al 2000), analysis of spontaneous and induced sputum 
(Lapperre et al 2004; Brightling et al 2005), and exhaled 
breath condensates (Biernacki et al 2003; Montuschi 
et al 2003) it has been possible to identify numerous 
inﬂ  ammatory mediators and cellular components of airway 
inﬂ  ammation in COPD (Bhowmik et al 2000; Rutgers et al 
Table 1 Cough and smoking habit as predictors of lung 
function decline in patients with established airﬂ  ow 
obstruction. Increasing smoking predicts a more rapid FEV1, 
especially in women. Mucus hyper-secretion in men also 
predicts decline. Reprinted from Vestbo J, Prescott E, Lange P. 
1996. Association of chronic mucus hypersecretion with FEV1 
decline and chronic obstructive pulmonary disease morbidity. 
Copenhagen City Heart Study Group. Am J Respir Crit Care Med, 
153:1530–5. Copyright © 1996 with permission from American 
Thoracic Society. 
    Men     Women 
   FEV1   p   FEV1   p 
 decline     decline   
Heavy Smokers   14.1   0.01   25.0   0.00001 
Medium Smokers   12.4   0.003   7.8   0.009 
Light Smokers   3.3   0.47   7.2   0.006 
Chronic Mucus   23.0   0.002   11.3   0.06 
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Figure 1 Chance of having airﬂ  ow obstruction with increasing age in smokers with or without cough (bars are 95% conﬁ  dence intervals). Reprinted from Van Schayck 
CP, Loozen JM, Wagena E, et al. 2002. Detecting patients at a high risk of developing chronic obstructive pulmonary disease in general practice: cross sectional case ﬁ  nding 
study. BMJ, 324:1370–5. Copyright © 2002 with permission from BMJ Publishing Group. International Journal of COPD 2006:1(3) 307
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2000; Gompertz et al 2001; Biernacki et al 2003; Montuschi 
et al 2003). Some inﬂ  ammatory mediators are known to be 
tussive agents such as prostaglandins (Choudry et al 1989), 
or indirectly implicated in cough reflex activation and 
mucus secretion, eg, tachykinins (Joos et al 2003). Whether 
these substances may be involved in stimulating cough or 
heightening cough reﬂ  ex sensitivity in COPD, and could be 
amenable to treatment, is unknown. 
Doherty et al (2000) investigated the cough reflex 
sensitivity to capsaicin in COPD and asthma compared 
with healthy volunteers. In this group of COPD hospital 
out-patients, with a mean FEV1 of 42% predicted, 81% 
of patients complained of cough on most days, despite 
there being no selection for the symptom of cough. The 
median cough threshold was signiﬁ  cantly reduced (ie, reﬂ  ex 
sensitivity increased) compared with healthy controls and 
similar to subjects with asthma (Figure 2). Other smaller 
studies have failed to replicate this ﬁ  nding (Fujimura et al 
1998; Dicpinigaitis 2001); this may be due to study size, 
differences in challenge methodology, or to differences in the 
severity of the disease in the patients included. The capsaicin 
sensitivity was moderately related to cough diary scores over 
a 2-week period (r= –0.44, p=<0.05) but completely unrelated 
to airﬂ  ow obstruction (Figure 3).
Mechanical sputum clearance by cough is also important. 
The accumulation of inﬂ  ammatory mucus exudates in the 
small airways has been recently shown to be strongly 
associated with disease progression (Hogg et al 2004). This 
occurs due to a combination of mucus hyper-secretion and 
impaired ciliary clearance and is likely to mechanically 
stimulate coughing.
Smoking is the main risk factor for the development 
of COPD. Chronic bronchitis, ie, cough and sputum 
without airﬂ  ow obstruction, develops in 50% of smokers 
(Siafakas et al 1995) and, with smoking cessation, stops 
in the majority after 1.5 years (Friedman and Siegelaub 
1980). COPD develops in about 10%–20% of smokers. 
The lung health survey data suggest COPD patients with 
chronic cough are more likely to have greater number of 
pack-years of smoking, worse lung function, and are more 
likely to be current smokers (Kanner et al 1999). Smoking 
cessation in subjects with COPD reduced the prevalence 
of chronic cough by >80% after 5 years (Figure 4). It is 
likely that the effects of current smoking on cough are due 
to airway inﬂ  ammation, mucus hyper-secretion, and ciliary 
dysfunction. The acute effect of smoking on cough reﬂ  ex 
sensitivity in COPD is unknown. In healthy smokers the 
sensitivity to capsaicin is less than in healthy volunteers 
(Dicpinigaitis 2003).
Finally, there may be important co-morbidities which 
contribute to cough. In one study of COPD, occult 
bronchiectasis was found in 50% of patients, increasing the 
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Figure 2  Cumulative frequency at which subjects reached cough threshold (C5) for subjects with COPD and asthma compared with normal subjects. Reprinted 
from Doherty MJ, Mister R, Pearson MG. et al. 2000. Capsaicin responsiveness and cough in asthma and chronic obstructive pulmonary disease. Thorax, 55:643–9. 
Copyright © 2000 with permission from BMJ Publishing Group.International Journal of COPD 2006:1(3) 308
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volume of sputum to be cleared (Patel et al 2004). Gastro-
oesophageal reﬂ  ux disease, which is reported to be a common 
cause of cause of cough in chronic cough clinics, also seems 
to be common in patients with severe airﬂ  ow obstruction 
(Casanova et al 2004). Laryngopharyngeal reﬂ  ux (in the 
absence of typical heartburn) may be an important cause of 
chronic cough (Westcott et al 2004) but its prevalence in 
COPD is unknown.
How much do patients with COPD 
cough?
Surveys of respiratory symptoms in the general population, 
show a prevalence of 11.9% for chronic cough and sputum 
in young adults (European Respiratory Community Health 
Survey) (Cerveri et al 2003). Current smoking was by far 
the most signiﬁ  cant risk factor for chronic cough. A large 
international survey has documented the patient reporting 
of frequency of symptoms in COPD (The Confronting 
COPD Survey [Rennard et al 2002]). Patients were asked if 
there had been any period of 3 months or more in the previous 
year when they had experienced symptoms for a few days 
a week, or every day. Cough was reported as frequently 
as breathlessness by participants (cough 70% [46% daily], 
breathlessness 67% [45% daily], and phlegm 60% [40% 
daily]). Seventy-eight percent of the patients reported at least 
one of these symptoms either every day or most days during 
a 3-month period in the past year.
In a large longitudinal sample of Danish men (n=876 
random population sample), the predictive value of 
respiratory symptoms (including cough and sputum 
production) for hospitalization was examined over a 12-
year period (Vestbo and Rasmussen 1989). Cough had the 
greatest predictive value for subsequent hospital admission 
due to respiratory disease (odds ratio 3.29 adjusted for age 
and smoking) and due to COPD (Table 2). Cough also had the 
highest predictive value for treatment for airﬂ  ow obstruction 
(relative risk ratio 4.70).
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  Figure 3 Scatter plot of relationship between cough threshold (C5) and FEV1 for subjects with COPD and asthma Reprinted from Doherty MJ, Mister R, Pearson MG. 
et al. 2000. Capsaicin responsiveness and cough in asthma and chronic obstructive pulmonary disease. Thorax, 55:643–9. Copyright © 2000 with permission from BMJ 
Publishing Group.International Journal of COPD 2006:1(3) 309
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Clinical studies of cough in COPD
There are two main techniques for clinically assessing 
cough, subjective reporting, and cough counting. There have 
been only a limited number of clinical studies speciﬁ  cally 
focused on these measures in COPD, mainly because of the 
difﬁ  culties in objectively measuring cough severity.
In other respiratory diseases, subjective scores of cough 
severity have a poor correlation with objective cough 
frequency, especially at night (Archer and Simpson 1985; 
Hsu et al 1994). In chronic cough patients, Hsu et al (1994) 
showed a signiﬁ  cant modest correlation between daytime 
cough scores and cough counts, but not asthma. In COPD, 
our preliminary data again suggest a poor correlation between 
cough scores and cough frequency (Smith et al 2003). The 
discrepancy between subjective and objective measures 
of cough occurs for several reasons. Subjects probably 
rate the severity of their cough on more than frequency 
alone; length of paroxysms, the force of the cough, and 
the degree of disruption to daily activities and sleep may 
all be important. The severity of breathlessness induced by 
coughing in patients with more severe airﬂ  ow obstruction 
could also be a factor.
Objective cough counting 
Trained observers manually counting the number of cough 
sounds from sound or video recordings can achieve good 
levels of agreement (Woolf and Rosenberg 1964; Subburaj 
et al 1996). A range of healthcare professionals listening 
to cough sounds from patients with different diseases 
can accurately recognize the presence–absence of airway 
sputum, but are poor at specifying the patient’s disease 
(Smith et al 2006a). The development of an automated 
system for ambulatory cough counting, over at least 
24 hours, would revolutionize the study of cough and its 
importance in respiratory disease in general, and COPD 
in particular. It would allow the same sort of critical 
assessment of cough that the measurement of FEV1 brings to 
breathlessness. However, the technical challenges have been 
formidable.
First, there is no universally accepted deﬁ  nition of what 
exactly constitutes a cough for counting purposes – should 
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Figure 4 Proportion of COPD subjects reporting chronic cough by ﬁ  nal smoking 
status in A: subjects not reporting cough at start of study, B: subjects reporting 
cough at the start of the study. CS current smoker, IQ intermittent quitters and 
SQ sustained quitters. Reprinted from Kanner RE, Connett JE, Williams DE. et al. 
1999. Effects of randomized assignment to a smoking cessation intervention and 
changes in smoking habits on respiratory symptoms in smokers with early chronic 
obstructive pulmonary disease: the Lung Health Study. Am J Med, 106:410–16. 
Copyright © 1999 with permission from Excerpta Medica, Inc.
Table 2 Predictive values of respiratory symptoms on 
hospitalization due to COPD, expressed as odds ratios and 95% 
conﬁ  dence intervals. Cough had the greatest predictive value 
for hospitalization even when odds ratios are adjusted for age, 
smoking habits and FEV1. Reprinted from Vestbo J, Rasmussen 
FV. 1989. Respiratory symptoms and FEV1 as predictors of 
hospitalization and medication in the following 12 years due 
to respiratory disease. Eur Respir J, 2:710–5. Copyright © 
1989 with permission from European Respiratory Society 
Journals Ltd. 
    Hospitalization due to COPD 
Explanatory variables    Age and Smoking     Age, smoking habits 
 habits  and  FEV1 
Cough   5.4   3.3 
   (2.5-11.8)   (1.4-7.6) 
Mucus Hypersecretion   5.5   2.9 
   (2.7-11.4)   (1.3-6.6) 
Chronic Bronchitis   5.8   3.2 
   (2.6-12.6)   (1.3-7.7) 
Breathlessness   4.2   1.7 
   (2.0-8.9)   (0.7-4.1) International Journal of COPD 2006:1(3) 310
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a peel of coughs (ie, series of cough noises in one breath) 
constitute a single “cough”? The intuitive way to manually 
count coughs is to count the number of explosive cough 
phases. The explosive portion of the sound is the component 
the human ear recognizes as the cough (Figure 5A). This 
technique becomes difﬁ  cult in long peels of coughing with 
multiple explosive phases of progressively diminishing 
amplitude (Figure 5B). One way to resolve this difﬁ  culty 
is to quantify cough in terms of the amount of time spent 
coughing, ie, the number of seconds that contain at least one 
explosive cough sound (Smith et al 2002), but this measure 
does give any information about cough amplitude.
Since the human ear can tell when someone in the 
vicinity is coughing as opposed to talking, or washing the 
dishes, it would be imagined that establishing a computer 
algorithm based on sound analysis to do the same would 
Figure 5 Cough waveform patterns for (a) typical cough sound with a single explosive phase and (b) peel of cough sounds with multiple explosive phases.
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be a relatively simple matter. However, this is not the case. 
Excluding background noise and other respiratory noises 
such as guttural speech, throat clearing, and sneezing all 
have proved difficult. Furthermore, the cough acoustic 
signals from subjects of different gender, age, with/without 
sputum, and with different diseases are enormously variable. 
If the acoustic features of spontaneously occurring cough 
sounds are studied, it becomes clear that the variability of 
the waveforms within an individual subject can be greater 
than that between individuals with the same condition, and 
for many features the variability is greater than between 
different diseases (Smith et al 2004). The large variation 
in the acoustic properties of cough sounds is probably the 
explanation for the lack of an automated cough counting 
system to date.
The ﬁ  rst reports of making sound recordings to quantify 
cough frequency were published in the 1960s (Woolf and 
Rosenberg 1964). Initially laboratory-based studies were 
performed in heterogenous groups of patients (Woolf and 
Rosenberg 1964; Loudon and Brown 1967; Loudon 1976). 
In the past decade improvements in recording technology 
have allowed ambulatory recordings to be made, although 
equipment has been cumbersome and battery-life insufﬁ  cient 
for continuous recordings (Hsu et al 1994; Chang et al 1997). 
These studies have always been limited in size and scope by 
the laborious task of manually counting the cough sounds. 
With further improvements in digital recording techniques, 
data compression, and storage the process is finally 
becoming automated, with computer algorithms identifying 
cough sounds from their speciﬁ  c acoustic features with 
improving sensitivity and speciﬁ  city (Dalmasso et al 1999; 
Hiew et al 2002; Subburaj et al 2003; Morice et al 2004). 
Nevertheless, the studies on automated ambulatory devices 
remain extremely laborious, due to the need to constantly 
re-validate reﬁ  nements in technology and algorithms against 
gold standard manual counting. Two other techniques for 
counting cough have been suggested using impedance 
plethysmography (Coyle et al 2005) or electromyography 
(Hsu et al 1994; Munyard et al 1994) as second signals, 
but these are expensive, cumbersome and not validated for 
ambulatory use.
Quantifying cough in COPD
Despite the lack of an available automated technique, it has 
been possible, although extremely laborious, to perform 
studies manually counting cough in COPD patients. 
However, due to limited battery life of the recording 
devices, early studies may have missed periods early in the 
morning, when cough is particularly important for COPD 
patients. We have studied ambulatory cough in moderately 
severe stable COPD patients complaining of cough (Smith 
et al 2003).
Patients with COPD cough much more by day (median 
of 12.3 seconds coughing per hour, cs/hour) than by night 
(1.63 cs/hour). Cough frequency is unrelated to FEV1 
(r=0.03, p=0.88) and relates moderately to cough challenge 
threshold to citric acid (r=0.48, p=0.01). In these patients 
selected for the symptom of cough, the relationships 
between cough frequency and subjective scores of cough 
are weak to moderate (daytime r=0.37, p=0.03; overnight 
r=0.48, p=<0.01); the better agreement between night-time 
cough counts and subjective scores may indicate some 
sleep disturbance. There is real hope that automated cough 
counters will be developed in the next few years which will 
allow the exploration of these relationships in diverse and 
much larger patient groups.
Consequences of cough in COPD
Quality of life
The presence of cough is commonly reported by patients 
with COPD but this gives no information about the 
impact of the symptom on health status. The St Georges 
Respiratory Questionnaire (SGRQ) and the Medical 
Research Council respiratory symptoms questionnaires 
have been extensively used and have both cross-sectional 
and longitudinal validity. During the development of 
the SGRQ a multivariate model was used to assess the 
effect of a number of measures of disease activity on the 
total score (Jones et al 1992). The reported presence of 
cough accounts for only a small portion of the variance 
in SGRQ scores (approximately 2%) compared with 
breathlessness or wheeze. However, only 50% of the 
variance is explained by the traditional clinical measures 
of disease severity. Furthermore the mean FEV1 in the 
patients studied was 47%; hence breathlessness is likely 
to be their overwhelming symptom.
More recently, cough-speciﬁ  c quality of life measures 
have been developed in the US (French et al 2002) and in 
the UK (Birring et al 2003). These questionnaires have been 
developed for use in patients attending chronic cough clinics. 
Whether these measures have validity in other conditions 
such as COPD is unexplored. Preliminary data have been 
presented on the scores for the LCQ and the CQLQ, and 
shown comparable impairment of cough speciﬁ  c quality 
of life between COPD and chronic cough subjects (Yaman 
et al 2003).International Journal of COPD 2006:1(3) 312
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Effects of treatments on cough in 
COPD
It could be suggested that cough is a protective mechanism 
for sputum clearance in COPD, and that suppressing 
cough with anti-tussives might even be harmful. 
However, a clinical trial of cough during antibiotic 
treatment of exacerbations of cystic fibrosis provides 
some insight into this problem (Smith et al 2006b). In this 
study, cough rates were very high during the acute phase 
and correlated with both systemic and airway measures 
of inflammation. However, after antibiotic treatment, 
cough rates were substantially lower, and correlated 
with sputum volume, but not with inflammatory markers. 
This advances the concept that treatment attacking the 
inflammatory component of cough in COPD might 
be symptomatically helpful without impeding sputum 
clearance.
The extent to which inhaled bronchodilators, 
corticosteroids, and anti-cholinergics affect cough in COPD 
is not clear. The relationships between prescribed treatment 
and cough reﬂ  ex sensitivity in COPD were examined in 
the study by Doherty et al (2000). There was no difference 
in the cough reﬂ  ex sensitivity between patients on and off 
inhaled steroids, but patients using inhaled anti-cholinergic 
treatment had a more sensitive cough reﬂ  ex than those 
without. In COPD patients complaining of cough and 
assessed by objective cough frequency a similar pattern is 
seen (Smith et al 2004). There was no association between 
cough frequency and dose of inhaled steroid. Subjects on 
inhaled long-acting β2-agonists had lower cough rates 
than those just on short-acting treatments but the opposite 
effect was seen for inhaled anti-cholinergic treatments, 
with treated patients having higher cough rates. A study of 
cough clearance of radio-labeled particles in COPD found 
clearance following ipratropium bromide was slower than 
following placebo (Bennett et al 1993). This suggestion of 
differential effects of treatments on cough in COPD needs 
re-appraizing in large, randomized, placebo-controlled 
clinical trials.
There are very few studies of the effect of cough 
suppressants in COPD. A small laboratory-based study (8 
patients) used a rather unreliable method of quantifying 
cough; patients recorded their own coughs using a manual 
click device, but found a 30% reduction in cough rate after 
codeine syrup compared with placebo. The study may have 
been only single blind, however (codeine syrup is bitter to 
taste) (Sevelius and Colmore 1966).
Recently we have published a randomized, double-blind, 
placebo-controlled, cross-over trial on the effect of two 
doses of codeine (60 mg) on cough frequency in patients 
with COPD (Smith et al 2005). Patients performed day 
and overnight cough recordings at baseline to conﬁ  rm a 
minimum cough rate, then 20 subjects were studied at day 
7 and 14 after 60-mg doses of codeine or identical placebo. 
Both codeine and placebo were associated with lower 
cough frequency compared with baseline, but there was no 
signiﬁ  cant difference between codeine and placebo in cough 
scores or citric acid cough sensitivity. This underscores the 
critical importance of placebo-controlled studies in cough 
in COPD. 
Conclusions
In conclusion, it is likely that multiple mechanisms 
contribute to stimulation of cough in COPD and their 
relative contributions remain to be elucidated. Established 
cough suppressants may not be effective in improving 
cough in COPD but an approach aimed at suppressing the 
inﬂ  ammatory component of cough may be effective.
Cough is a signiﬁ  cant predictor of decline in patients 
with established airﬂ  ow obstruction and may be an indicator 
of mild disease in case-ﬁ  nding in the community. Cough 
is independently associated with disability in COPD, but 
evidence from patient health status scores suggest that 
breathlessness rather than cough is increasingly important 
as severity increases. The interactions between cough and 
breathlessness with regard to health status have not been 
investigated.
Stable COPD patients cough much more by day than 
night and patients seem to be sensitive to the time spent 
coughing, as in large surveys the presence of the symptom 
is very commonly reported. Objective cough counts provide 
new insights, and ultimately automated cough counting 
will provide a new objective outcome measures in COPD. 
This will allow exploration of areas about which we know 
very little, such as correlations with inﬂ  ammatory markers 
and precise changes to cough during acute exacerbations 
of COPD.
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